Clinical trialNCT06574880RecruitingPhase 1/PHASE2Interventional

STereotActic Body Radiotherapy and 177Lutetium PSMA in Locally Advanced Prostate Cancer

SponsorAngela Y. Jia, MD PhDEnrollment45Locally Advanced Prostate CancerMalignant Neoplasm of Prostate

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The goal of this clinical trial is to is to investigate if it is possible to lower the chance of cancer reoccurrence and also preserve quality of life by using the drug Pluvicto instead of androgen-deprivation therapy to the usual radiation therapy for advanced local prostate cancer. Participants will receive one dose of Pluvicto, followed by radiation about 6 weeks later. Radiation therapy will be completed in 5 treatments over the period of 2 weeks. A second dose of Pluvicto will be given 6 weeks after radiation is complete. Some participants may also receive a third dose of Pluvicto, and this would be given 6 weeks after the second dose of Pluvicto.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Angela Y Jia, MD, PhD
University Hospitals Cleveland Medical Center, Case Comprehensive Cancer Center
Principal Investigator
clinicaltrials.gov ↗
Daniel E Spratt, MD
University Hospitals Cleveland Medical Center, Case Comprehensive Cancer Center
Study ChairKOL profile →
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

University Hospitals Cleveland Medical Center Seidman Cancer Center, Case Comprehensive Cancer Center
Cleveland, Ohio, United States
Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Lu-PSMA-617

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 13 May 2025
Primary completion: 1 Sept 2026
Completion: 1 Mar 2027
Last update posted: 26 May 2026
Registered enrollment: 45
Registry id: NCT06574880

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.